Image
Interactive Exchangeâ„¢

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Meeting Slides

Suggested Readings

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.

Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Lancet. 2013;382(9889):339-352.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Inzucchi SE, Zinman B, Wanner C, et al. Diab Vasc Dis Res. 2015;12(2):90-100.

Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

King RJ, Grant PJ. Herz. 2016;41(3):184-192.

Diabetes mellitus and heart failure.

Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.

Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.

Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019. [Epub ahead of print]

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.

Mosenzon O, Wiviott SD, Cahn A, et al. Lancet Diabetes Endocrinol. 2019;7(8):606-617.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med. 2017;377(7):644-657.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.

Diabetic kidney disease.

Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.

Diabetic kidney disease: pathophysiology and therapeutic targets.

Toth-Manikowski S, Atta MG. J Diabetes Res. 2015;2015:697010.

SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.

van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.

Empagliflozin and progression of kidney disease in type 2 diabetes.

Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.

Interactive Presentation

Connecting T2DM Pathophysiology, Comorbidities, and SGLT2 Inhibitors

Presented by Derek LeRoith, MD, PhD


Activity
Multidimensional Issues in Type 2 Diabetes

Debates and Discussions Around Cardiovascular and Renal Outcomes

Activity
Multidimensional Outcomes in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Activity
Multidimensional Outcomes in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Making the Call in Heart Failure

Multidimensional Outcomes With SGLT2 Inhibitors

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes

Flexing Your Muscles in Familial Hypercholesterolemia

Best Practices for Screening, Diagnosis, and Management